Mechanisms of resistance to intermittent androgen deprivation in patients with prostate cancer identified by a novel computational method

Jason D. Morken, Aaron Packer, Rebecca A. Everett, John D. Nagy, Yang Kuang

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

For progressive prostate cancer, intermittent androgen deprivation (IAD) is one of the most common and effective treatments. Although this treatment is usually initially effective at regressing tumors, most patients eventually develop castration-resistant prostate cancer (CRPC), for which there is no effective treatment and is generally fatal. Although several biologic mechanisms leading to CRPC development and their relative frequencies have been identified, it is difficult to determine which mechanisms of resistance are developing in a given patient. Personalized therapy that identifies and targets specific mechanisms of resistance developing in individual patients is likely one of the most promising methods of future cancer therapy. Prostate-specific antigen (PSA) is a biomarker for monitoring tumor progression. We incorporated a cell death rate (CDR) function into a previous dynamical PSA model that was highly accurate at fitting clinical PSA data for 7 patients. The mechanism of action of IAD is largely induction of apoptosis, and each mechanism of resistance varies in its CDR dynamics. Thus, we analyze the CDR levels and their time-dependent oscillations to identify mechanisms of resistance to IAD developing in individual patients.

Original languageEnglish (US)
Pages (from-to)3673-3683
Number of pages11
JournalCancer Research
Volume74
Issue number14
DOIs
StatePublished - Jul 15 2014

Fingerprint

Androgens
Prostatic Neoplasms
Prostate-Specific Antigen
Cell Death
Castration
Mortality
Therapeutics
Tumor Biomarkers
Neoplasms
Apoptosis

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Mechanisms of resistance to intermittent androgen deprivation in patients with prostate cancer identified by a novel computational method. / Morken, Jason D.; Packer, Aaron; Everett, Rebecca A.; Nagy, John D.; Kuang, Yang.

In: Cancer Research, Vol. 74, No. 14, 15.07.2014, p. 3673-3683.

Research output: Contribution to journalArticle

Morken, Jason D. ; Packer, Aaron ; Everett, Rebecca A. ; Nagy, John D. ; Kuang, Yang. / Mechanisms of resistance to intermittent androgen deprivation in patients with prostate cancer identified by a novel computational method. In: Cancer Research. 2014 ; Vol. 74, No. 14. pp. 3673-3683.
@article{5bb2d48e50e5435982cf86866d09470d,
title = "Mechanisms of resistance to intermittent androgen deprivation in patients with prostate cancer identified by a novel computational method",
abstract = "For progressive prostate cancer, intermittent androgen deprivation (IAD) is one of the most common and effective treatments. Although this treatment is usually initially effective at regressing tumors, most patients eventually develop castration-resistant prostate cancer (CRPC), for which there is no effective treatment and is generally fatal. Although several biologic mechanisms leading to CRPC development and their relative frequencies have been identified, it is difficult to determine which mechanisms of resistance are developing in a given patient. Personalized therapy that identifies and targets specific mechanisms of resistance developing in individual patients is likely one of the most promising methods of future cancer therapy. Prostate-specific antigen (PSA) is a biomarker for monitoring tumor progression. We incorporated a cell death rate (CDR) function into a previous dynamical PSA model that was highly accurate at fitting clinical PSA data for 7 patients. The mechanism of action of IAD is largely induction of apoptosis, and each mechanism of resistance varies in its CDR dynamics. Thus, we analyze the CDR levels and their time-dependent oscillations to identify mechanisms of resistance to IAD developing in individual patients.",
author = "Morken, {Jason D.} and Aaron Packer and Everett, {Rebecca A.} and Nagy, {John D.} and Yang Kuang",
year = "2014",
month = "7",
day = "15",
doi = "10.1158/0008-5472.CAN-13-3162",
language = "English (US)",
volume = "74",
pages = "3673--3683",
journal = "Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "14",

}

TY - JOUR

T1 - Mechanisms of resistance to intermittent androgen deprivation in patients with prostate cancer identified by a novel computational method

AU - Morken, Jason D.

AU - Packer, Aaron

AU - Everett, Rebecca A.

AU - Nagy, John D.

AU - Kuang, Yang

PY - 2014/7/15

Y1 - 2014/7/15

N2 - For progressive prostate cancer, intermittent androgen deprivation (IAD) is one of the most common and effective treatments. Although this treatment is usually initially effective at regressing tumors, most patients eventually develop castration-resistant prostate cancer (CRPC), for which there is no effective treatment and is generally fatal. Although several biologic mechanisms leading to CRPC development and their relative frequencies have been identified, it is difficult to determine which mechanisms of resistance are developing in a given patient. Personalized therapy that identifies and targets specific mechanisms of resistance developing in individual patients is likely one of the most promising methods of future cancer therapy. Prostate-specific antigen (PSA) is a biomarker for monitoring tumor progression. We incorporated a cell death rate (CDR) function into a previous dynamical PSA model that was highly accurate at fitting clinical PSA data for 7 patients. The mechanism of action of IAD is largely induction of apoptosis, and each mechanism of resistance varies in its CDR dynamics. Thus, we analyze the CDR levels and their time-dependent oscillations to identify mechanisms of resistance to IAD developing in individual patients.

AB - For progressive prostate cancer, intermittent androgen deprivation (IAD) is one of the most common and effective treatments. Although this treatment is usually initially effective at regressing tumors, most patients eventually develop castration-resistant prostate cancer (CRPC), for which there is no effective treatment and is generally fatal. Although several biologic mechanisms leading to CRPC development and their relative frequencies have been identified, it is difficult to determine which mechanisms of resistance are developing in a given patient. Personalized therapy that identifies and targets specific mechanisms of resistance developing in individual patients is likely one of the most promising methods of future cancer therapy. Prostate-specific antigen (PSA) is a biomarker for monitoring tumor progression. We incorporated a cell death rate (CDR) function into a previous dynamical PSA model that was highly accurate at fitting clinical PSA data for 7 patients. The mechanism of action of IAD is largely induction of apoptosis, and each mechanism of resistance varies in its CDR dynamics. Thus, we analyze the CDR levels and their time-dependent oscillations to identify mechanisms of resistance to IAD developing in individual patients.

UR - http://www.scopus.com/inward/record.url?scp=84904266407&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84904266407&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-13-3162

DO - 10.1158/0008-5472.CAN-13-3162

M3 - Article

C2 - 24853547

AN - SCOPUS:84904266407

VL - 74

SP - 3673

EP - 3683

JO - Cancer Research

JF - Cancer Research

SN - 0008-5472

IS - 14

ER -